DK3320099T3 - Membranforankret eller udskilt antistof til ekspression af lentivirale vektorer - Google Patents

Membranforankret eller udskilt antistof til ekspression af lentivirale vektorer Download PDF

Info

Publication number
DK3320099T3
DK3320099T3 DK16738128.4T DK16738128T DK3320099T3 DK 3320099 T3 DK3320099 T3 DK 3320099T3 DK 16738128 T DK16738128 T DK 16738128T DK 3320099 T3 DK3320099 T3 DK 3320099T3
Authority
DK
Denmark
Prior art keywords
anchored
membrane
expression
lentiviral vectors
secreted antibody
Prior art date
Application number
DK16738128.4T
Other languages
English (en)
Inventor
Floriane Fusil
Els Verhoeyen
Thierry Defrance
François-Loïc Cosset
Original Assignee
Inst Nat Sante Rech Med
Univ Claude Bernard Lyon
Ecole Normale Superieure Lyon
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Claude Bernard Lyon, Ecole Normale Superieure Lyon, Centre Nat Rech Scient filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of DK3320099T3 publication Critical patent/DK3320099T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16738128.4T 2015-07-09 2016-07-08 Membranforankret eller udskilt antistof til ekspression af lentivirale vektorer DK3320099T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15306132 2015-07-09
PCT/EP2016/066349 WO2017005923A1 (en) 2015-07-09 2016-07-08 Lentiviral vector expressing membrane-anchored or secreted antibody

Publications (1)

Publication Number Publication Date
DK3320099T3 true DK3320099T3 (da) 2023-12-11

Family

ID=53673045

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16738128.4T DK3320099T3 (da) 2015-07-09 2016-07-08 Membranforankret eller udskilt antistof til ekspression af lentivirale vektorer

Country Status (5)

Country Link
US (2) US11623950B2 (da)
EP (1) EP3320099B1 (da)
DK (1) DK3320099T3 (da)
ES (1) ES2965292T3 (da)
WO (1) WO2017005923A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
AU2019232523A1 (en) * 2018-03-05 2020-09-03 Etablissement Francais Du Sang Recombinant single chain immunoglobulins
EP3844290A4 (en) * 2018-09-13 2022-07-06 Ramot at Tel-Aviv University Ltd. GENETIC MODIFICATION OF B-LYMPHOCYTE RECEPTORS AND THEIR USES IN ANTIGEN-INDUCED ANTIBODY SECRETION
AU2022216314A1 (en) * 2021-02-07 2023-09-14 Baylor College Of Medicine Engineered nkt cells for expansion and in vivo preservation and methods of use for the control of tumor cells
CA3219487A1 (en) * 2021-05-28 2022-12-01 Richard C. Mulligan Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses
WO2023114884A2 (en) * 2021-12-15 2023-06-22 Interius Biotherapeutics, Inc. Pseudotyped viral particles, compositions comprising the same, and uses thereof
WO2023133595A2 (en) * 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE50115580D1 (de) * 2001-10-01 2010-09-16 Deutsches Krebsforsch Verfahren zur Herstellung von Protein-Bibliotheken und zur Selektion von Proteinen daraus
CN100360565C (zh) * 2001-12-22 2008-01-09 4-抗体股份公司 制备脊椎动物淋巴细胞和生产结合蛋白的方法
KR20070073885A (ko) * 2004-10-05 2007-07-10 뉴랄랩 리미티드 재조합 단백질 생산을 향상시키는 방법 및 조성물
US7878409B2 (en) * 2005-12-09 2011-02-01 Shoplogix Inc. System and method for verifying identity during data entry with a barcode scanner
WO2007131774A1 (en) * 2006-05-17 2007-11-22 F. Hoffmann-La Roche Ag Polypeptide producing cells
US7732195B2 (en) * 2006-11-01 2010-06-08 Facet Biotech Corporation Tethered vectors for cell surface immunoglobulin display
WO2009059235A2 (en) 2007-11-01 2009-05-07 Facet Biotech Corporation Immunoglobulin display vectors
US8969539B2 (en) * 2008-06-11 2015-03-03 Jn Biosciences Llc Expression vectors
CN102272160A (zh) * 2008-12-31 2011-12-07 印度血清及疫苗有限公司 抗rhd单克隆抗体
US20100303776A1 (en) * 2009-04-16 2010-12-02 The University Of North Carolina At Chapel Hill Methods and compositions for regulated expression of multiple nucleic acids
EP3366308A1 (en) * 2009-09-06 2018-08-29 Protab Ltd. Humanized antibodies specific for hsp65-derived peptide-6 methods and uses thereof
CA2793309A1 (en) * 2010-03-17 2011-09-22 Anaptysbio, Inc. Method of producing transcripts using cryptic splice sites
JP7008406B2 (ja) * 2014-02-28 2022-01-25 イクノス サイエンシズ エスエー ポリペプチドを発現する宿主細胞を選択するための発現構築物および方法

Also Published As

Publication number Publication date
EP3320099B1 (en) 2023-09-13
ES2965292T3 (es) 2024-04-12
WO2017005923A1 (en) 2017-01-12
US20230340085A1 (en) 2023-10-26
US11623950B2 (en) 2023-04-11
US20180371064A1 (en) 2018-12-27
EP3320099A1 (en) 2018-05-16

Similar Documents

Publication Publication Date Title
DK3538965T3 (da) Sikkerhedssystem til drift af et ubemandet luftfartøj
CL2018000370A1 (es) Nuevos anticuerpos anti-pd-1
DK3455257T3 (da) Anti-pd-l1-antistoffer
DK3332006T3 (da) Hidtil ukendte anti-PD-L1-antistoffer
DK3320099T3 (da) Membranforankret eller udskilt antistof til ekspression af lentivirale vektorer
DK3371619T3 (da) Detektering af et ubemandet luftfartøj
DK3538864T3 (da) Mikrotom
DK3344654T3 (da) Anti-lag-3-antistoffer
DK3331876T3 (da) Modulators of ror-gamma
DK3277717T3 (da) En hidtil ukendt il33-form, muterede former af il33, antistoffer, assays og fremgangsmåder til anvendelse deraf
DK3556775T3 (da) Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
DK3259349T3 (da) Dehydrogenase-katalyseret fremstilling af FDCA
DK3563156T3 (da) Fremgangsmåde til separering af biomolekyler
DK3368683T3 (da) Fremgangsmåde til kvantifikationen af pd-l1
DK3377618T3 (da) Buffere til stabilisering af lentivirus-præparater
DK3287523T3 (da) Fremgangsmåde til sekretorisk fremstilling af protein
DK3458100T3 (da) Selektiv reduktion af cystein-manipulerede antistoffer
DK3515990T3 (da) Fremgangsmåde til fremstilling af lignocellulosematerialer
DK3250593T3 (da) Anti-transthyretin-antistoffer
DK3487443T3 (da) Fremgangsmåde til opmåling af en implantat-implantat-situation
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3201346T3 (da) Fremgangsmåder til fremstilling af biopolymer-matrix kompositmaterialer
DK3148642T3 (da) Anordning til profylakse af hørenedsættelse eller vertigo